IMV102 / Immunofoco - LARVOL DELTA

IMV102, an in vivo BCMA-targeting CAR-T therapy, achieves durable tumor control in multiple myeloma models (AACR 2026) - "Treatment was well tolerated, with no significant weight loss observed.ConclusionsIMV102 enables efficient and selective in vivo generation of functional BCMA CAR-T cells, resulting in potent and durable antitumor activity in multiple myeloma models. These results pave the way for further clinical investigation."

CAR T-Cell Therapy • IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • CD4 • CD8 • IFNG